StockNews.com Upgrades Akebia Therapeutics (NASDAQ:AKBA) to Hold
Akebia Therapeutics (NASDAQ:AKBA – Get Free Report) was upgraded by StockNews.com from a “sell” rating to a “hold” rating in a report issued on Monday. Other equities analysts also recently issued research reports about the stock. Piper Sandler increased their price target on shares of Akebia Therapeutics from $4.00 to $6.00 and gave the company […]
Akebia Therapeutics (NASDAQ:AKBA – Get Free Report) was upgraded by StockNews.com from a “sell” rating to a “hold” rating in a report issued on Monday. Other equities analysts also recently issued research reports about the stock. Piper Sandler increased their price target on shares of Akebia Therapeutics from $4.00 to $6.00 and gave the company […]
